Trial
NCT06152523
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
MSI
Intervention
Monalizumab/MEDI5257
Why stopped
The study has been halted because the manufacturer can no longer supply the experimental treatment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-06